Ceftiofur, an extended-spectrum cephalosporin, is active against a variety of animal pathogens, including organisms associated with swine respiratory disease. However, minimum inhibitory concentration (MIC) breakpoint and disk diffusion interpretive criteria have not been established for swine pathogens. Susceptibility tests were performed by broth microdilution MIC and disk diffusion methods on 246 bacterial species that cause swine respiratory disease. Ceftiofur was active against Salmonella sp., Pasteurella multocida, Actinobacillus pleuropneumoniae, Streptococcus suis, and Escherichia coli but was not active against Bordetella bronchiseptica measured by MIC. Based on pharmacokinetic studies of ceftiofur in swine after a single intramuscular injection of 3 or 5 mg/kg body weight of ceftiofur and on the MIC and disk diffusion data, we recommend MIC breakpoints and disk diffusion distances, respectively, of ≤ 2 µg/ml and ≥ 21 mm for susceptible, 4 µg/ml and 18-20 mm for intermediate, and ≥ 8 µg/ml and ≤ 17 mm for resistant classification for swine pathogens. When these breakpoints were applied to data from a previous study using bovine pathogens, only 1 minor interpretive error occurred.
Swine respiratory disease is an economically important disease to swine producers 1, 13 . The etiology of swine respiratory disease is complex; it may be caused by a variety of organisms, either alone or in combination, but the species commonly implicated include Actinobacillus pleuropneumoniae, Pasteurella multocida, Salmonella choleraesuis, Escherichia coli, Streptococcus suis, and Mycoplasma hyopneumoniae. 1, 12, 13 Antimicrobial therapy is an important component of programs to reduce both the morbidity and mortality associated with swine respiratory disease. 1, 12, 13 Ceftiofur is an extended-spectrum cephalosporin that is active against a variety of animal pathogens. 15 It was approved by the Food and Drug Administration in 1988 for use in the treatment of bovine respiratory disease. At that time, minimum inhibitory concentration (MIC) breakpoint and zone interpretive criteria were recommended based upon the microbiology and the pharmacokinetics of ceftiofur in cattle. disease with a dose range of 3-5 mg/kg/day, but MIC breakpoints and zone interpretive criteria have not been established.
The purpose of this study was to establish interpretive criteria for swine respiratory disease pathogens based upon the pharmacokinetics of ceftiofur in swine, broth microdilution MIC, and agar disk diffusion data generated for swine pathogens.
Materials and methods
Bacterial strains. The 246 bacterial isolates used in this study were obtained from Pharmacia and Upjohn (Kalamazoo, MI) and from Lorraine Hoffman at the Veterinary Diagnostic Laboratory (Iowa State University, Ames, IA). The isolates were comprised of bacterial species known as causative agents of swine respiratory disease and included 51 Salmonella sp., 48 P. multocida, 49 A. pleuropneumoniae, 22 Streptococcus suis, 51 E. coli, and 25 B. bronchiseptica isolates. The strains were shipped to our laboratory (Franklin, TN) on agar slants, where they were subcultured to chocolate or 5% sheep blood agar plates a and incubated at 35 C in ambient air. After 18-24 hr of incubation, the isolates were checked for purity and frozen in sheep blood at -80 C until further testing.
Antimicrobial susceptibility testing. Susceptibility testing was performed in duplicate on each isolate using standardized methods as recommended by the National Committee for Clinical Laboratory Standards (NCCLS) to determine broth microdilution MICS. 9 For MIC susceptibility testing, serial 2-fold dilutions of ceftiofur b were prepared in 96-well microtiter plates using Mueller-Hinton broth a except when testing A. pleuropneumoniae, for which the Mueller-Hinton broth was supplemented with 2-5% lysed horse blood. These plates were stored at -80 C until ready to use and then thawed to room temperature. For the preparation of the inoculum, the frozen bacterial strains were thawed at room temperature, subcultured to agar medium, and incubated 18-20 hr.
Three to five isolated colonies of each strain were suspended in tryptic soy broth, and the turbidity was adjusted to equal a 0.5 MacFarland standard (approximately 10 8 colony-forming units [CFU]/ml). The suspension was further diluted in saline to achieve a final inoculum concentration of approximately 5 x 10 5 CFU/ml in each microdilution we11. 9 After 16-20 hr of incubation, the MIC end points were read as the lowest concentration of antibiotic that inhibited visible growth.
Disk diffusion susceptibility testing was also performed in duplicate on each isolate using the method recommended by the NCCLS guidelines. 10 All organisms were tested on commercially prepared Mueller-Hinton agar plates" with the exceptions of S. suis, which was tested on Mueller-Hinton supplemented with 5% sheep blood, a and A. pleuropneumoniae, which was tested on chocolate Mueller-Hinton agar. c The strains were prepared for testing as described above, and the inoculum was adjusted to equal a turbidity of a 0.5 Mac-Farland standard by making a direct suspension of several individual colonies in tryptic soy broth. 10 The cellular suspension was transferred to the appropriate medium by swabbing the suspension over the entire dried agar surface. In these studies, we used the 30-µg ceftiofur disk b that had been recommended for the bovine respiratory disease isolates. After 16-20 hr of incubation, each plate was examined and the diameters of the zones of no visible bacterial growth surrounding the disk were measured.
The pharmacokinetic studies for ceftiofur were conducted in the Pharmacia & Upjohn laboratories using a single intramuscular injection of either 3 or 5 mg/kg body weight of ceftiofur. Eight pigs, (4 males and 4 females) were used in the study. Two males and 2 females received the 3 mg/kg dose of ceftiofur, and the remaining 4 animals received the 5 mg/kg dose. Blood samples were obtained from an ear vein at various times, and the plasma portion of the blood was analyzed by high-pressure liquid chromatography for desfuroyl-ceftiofur, the major metabolite of ceftiofur that has microbiological activity. 5 The MICs and zone diameters were plotted in a scattergram, and the method of error rate bounding and linear regression were used to determine interpretive breakpoints. 8, 11 The MIC breakpoints for ceftiofur against swine pathogens were determined from the pharmacokinetic data for swine. Using the scattergram and the MIC breakpoints, and error rate bounding the zone diameter breakpoints was determined.
Results and discussion
The concentrations of ceftiofur attained in swine following a single dose of either 3 or 5 mg of ceftiofur/ kg body weight are shown in Fig. 1 . Differences in the 2 curves were minimal: peak concentrations of 15.5 and 16.5 µg/ml were achieved at 1.0 hour with the 3 and 5 mg/kg dosing, respectively. After dosing by either regimen, the drug levels exceeded 2 µg/ml at 24 hours.
The susceptibility results by broth MIC and disk diffusion are shown in Table 1 and Fig. 2 . All isolates except for B. bronchiseptica had MICs that were ≤ 2 µg/ml and zone diameters that were ≥ 22 mm. The B. bronchiseptica isolates were generally resistant, with most (64%) having MICs of ≥ 32 µg/ml and no zone of inhibition (6 mm). Based on the MIC 90 s, the order of activity of ceftiofur, from most susceptible to least susceptible, was P. multocida > A. pleuropneumoniae > S. suis > E. coli > Salmonella sp. > B. bronchiseptica. These data essentially confirm previously reported results for the activity of ceftiofur. 14 Although the pharmacokinetics, safety, and clinical efficacy of ceftiofur have been studied in swine, most studies have used isolates from cattle and horses. [2] [3] [4] [5] [6] 7, 14 The isolates in this study were from swine and yielded results similar to those using bovine and equine isolates.
Based on the pharmacokinetics of ceftiofur in swine and on the MICs of the 246 isolates that were tested, the choice of breakpoints appeared to be natural ones when the population distribution was examined. Because the peak blood levels of ceftiofur were 14-16 µg/ ml, with either 3 mg/kg or the 5 mg/kg dosing, and the levels at 24 hours were >2 µg/ml, we chose ≤ 2 µg/ml as the susceptible MIC breakpoint. Because we included an intermediate (or buffer) MIC at 4 µg/ml, the resistant MIC breakpoint was ≥ 8 µg/ml. With these MIC breakpoints and the distribution of isolates as shown in Fig. 2 , the disk diffusion zone criteria were determined to be ≥ 21 mm for susceptible, 18-20 mm for intermediate, and ≤ 17 mm for resistant. With these breakpoints, there were no interpretive errors.
In another study of ceftiofur and bovine respiratory disease pathogens, breakpoints similar to these have been tentatively recommended (J. Steffan and H. Mor-van, unpublished data). These authors recommended the same MIC breakpoints (i.e., ≤ 2 µg/ml indicating susceptibility, 4 µg/ml indicating intermediate susceptibility, and ≥ 8 µg/ml indicating resistance). Their recommendations for disk diffusion breakpoints, however, were slightly different, with ≥ 24 mm indicating susceptibility, 20-23 mm indicating intermediate susceptibility, and ≤ 19 mm indicating resistance, in contrast to our recommendations for swine pathogens of ≥ 21 mm 18-20 mm, and ≤ 17 mm, respectively. The scattergram of their MICs and zone diameters is very similar to ours, and the breakpoints we recommend would be suitable for their data, with the only discrepancy being 1 minor error among the 95 isolates tested in their study. However, the zone diameters they recommended would not be ideal for our data with swine pathogens. Therefore, we recommend that the breakpoints of ≥ 21 mm for susceptible, 18-20 mm for intermediate, and ≤ 17 mm for resistant be used for both swine and bovine isolates because the data from both group of pathogens yielded nearly equivalent breakpoints.
Infections with strains of swine respiratory disease pathogens such as Salmonella sp., P. multocida, A. pleuropneumoniae, Streptococcus suis, and E. coli should respond to therapy with ceftiofur, but infections due to B. bronchiseptica are unlikely to respond. A study of experimentally induced E. coli enteric infections in neonatal pigs showed that ceftiofur was efficacious when modalities such as reductions in mortality, shedding of bacteria, diarrhea, and increases in body weight in treated animals were compared with untreated animals. 14 Two other studies also showed that ceftiofur provided adequate treatment of swine respiratory disease caused by a variety of pathogens, including A. pleuropneumoniae. 2, 6 In conclusion, Salmonella spp., P. multocida, A. pleuropneumoniae. S. suis, E. coli, and B. bronchiseptica isolates should be tested for susceptibility by either the MIC or disk diffusion methods recommended by the NCCLS 9,10 using breakpoint MICs of ≤ 2 µg/ml and zones of ≥ 21 mm for susceptible, MICs of 4 µg/ml and zones of 18-20 mm for intermediate, and MICs of ≥ 8 µg/ml and zones of ≤ 17 mm for resistant. 
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